Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.

ABSTRACT:

Objectives

Based on our previous findings that postmenopausal women with estrone (E1) and estradiol (E2) concentrations at or above 1.3 pg/ml and 0.5 pg/ml, respectively, after 6 months of adjuvant anastrozole therapy had a three-fold risk of recurrence, we aimed to identify a single-nucleotide polymorphism (SNP)-based model that would predict elevated E1 and E2 and then validate it in an independent dataset.

Patients and methods

The test set consisted of 322 women from the M3 study and the validation set consisted of 152 patients from MA.27. All patients were treated with adjuvant anastrozole, had on-anastrozole E1 and E2 concentrations and genome-wide genotyping.

Results

SNPs were identified from the M3 genome-wide association study. The best model to predict the E1

SUBMITTER: Ingle JN 

PROVIDER: S-EPMC7655717 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature